COMP <GO>
NUTX vs PG // PIOTROSKI F-SCORE QUALITY
Nutex Health Inc. (NASDAQ) VS. Procter & Gamble Company (NYSE) • 15-METRIC TALLY: NUTX 7
— PG 6
▲ PIOTROSKI F-SCORE QUALITY LEADER: NUTX
LAST: $210.10 (-1.19%) • MKT CAP: $1.44B
piotroski-score
9/9
LAST: $160.59 (+1.47%) • MKT CAP: $372.21B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUTX VS. PG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NUTX | PG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.80% | 51.20% | -0.40 | PG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 25.40% | +59.60 | NUTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 4.6x | 16.2x | -11.60 | NUTX | /valuation <GO> |
| Free Cash Flow Yield | 17.07% | 3.77% | +13.30 | NUTX | /fcf-yield <GO> |
| Operating Margin | 31.50% | 24.30% | +7.20 | NUTX | /operating-margins <GO> |
| Net Profit Margin | 8.10% | 19.00% | -10.90 | PG | /net-margins <GO> |
| Revenue Growth (YoY) | 82.40% | 0.30% | +82.10 | NUTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.65% | -2.65 | PG | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.75 | 5.59 | -1.84 | PG | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 9/9 | 7/9 | +2.00 | NUTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 60.3 | -13.62 | PG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.87 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.1x | 21.7x | -4.60 | NUTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.44B | $372.21B | -$370.77B | PG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NUTX REV | PG REV | NUTX GROSS % | PG GROSS % | NUTX FCF | PG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $875.3M | $84.28B | 50.8% | 51.2% | $245.6M | $14.04B |
| FY 2024 | $479.9M | $84.04B | 40.9% | 51.4% | $20.8M | $16.52B |
| FY 2023 | $247.6M | $82.01B | — | — | $1.3M | $13.16B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUTX // BETA —
PG // BETA 0.87